Cerebral Oximetry Monitoring Market Size was valued at USD 0.11 Billion in 2023. The Cerebral Oximetry Monitoring market Age is projected to grow from USD 0.12 Billion in 2024 to USD 0.19 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.10% during the forecast period (2024 - 2032). The ageing population and the prevalence of illnesses including cardiovascular and neurological conditions, are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
The primary drivers of the market's growth are the expanding geriatric population and the rising incidence of ailments including cardiovascular and neurological problems. The adoption of the western lifestyle, heavy smoking, alcohol consumption, and physical inactivity led to an estimated 697,000 Americans having coronary artery disease (CAD) in 2020, according to the centres for disease control and prevention (CDC). The demand for cerebral oximetry monitoring equipment to perform safe CAD surgery is anticipated to increase as the number of CAD cases rises.
It has been noted that regulatory organisations like the U.S. FDA and EMA approve new cerebral oximeter devices, providing market participants with a business opportunity. As cerebral oximeters are one of the most crucial tools used to track the level of oxygen in the brain, the prevalence of neurological illnesses also increases the need for these instruments. Thus, it is projected that throughout the forecast period, market growth would be driven by the increasing acceptance of these devices and the device industry's ongoing evolution.
It is anticipated that the market would expand as a result of the combined usage of cerebral oximeters and other technologies. For instance, Medtronic integrated two continuous monitoring technologies into the CARESCAPE platform of G.E. Healthcare in June 2022, enabling physicians to personalise care. The ICU and surgical care will use the Microstream capnography and INVOS regional oximetry technology. The FDA has approved the integration, and the CE Mark has been obtained. The whole set of Medtronic patient monitoring technologies is now complete and accessible on the CARESCAPE platform. Additionally, the system features FlexAcuity from G.E. Healthcare, which enables physicians to select care alternatives depending on patient acuity requirements and identify deterioration early. Worldwide clinicians now have more alternatives for patient treatment thanks to this connection. Thus, driving the Cerebral Oximetry Monitoring market revenue.
The Cerebral Oximetry Monitoring market segmentation, based on age, includes adults and pediatrics. Adults segment dominated the market in 2022. The demand for devices is mostly driven by the rising approval and clearance of new gadgets to track adults' cerebral oxygen levels. During the forecast period, it is anticipated that the paediatric section will increase profitably. This expansion is due to the devices' expanded paediatric usage authorisation. The U.S. FDA granted Masimo an extension of permission in March 2022 to use its SedLine brain function system and sensors to track the brain activity of children under anaesthesia.
The Cerebral Oximetry Monitoring market segmentation, based on application, includes cardiac surgery, vascular surgery, and pediatrics. Cardiac surgery segment dominated the market in 2022. During cardiac surgery, the cerebral oximeter is crucial for monitoring the amount of oxygen reaching the brain. For instance, more than 2 million open heart procedures are carried out worldwide each year to address various cardiac problems, according to the National Heart, Lung, and Blood Institute. Thus, more procedures involving the heart are anticipated to fuel demand for cerebral oximetry devices during the course of the projected period. During the forecast period, it is anticipated that the other segment would grow significantly. Other segments cover operations related to orthopaedic and neurological problems.
The Cerebral Oximetry Monitoring market segmentation, based on end user, includes hospitals, clinics, ambulatory surgical centers, and others. Hospitals segment dominated the Cerebral Oximetry Monitoring market in 2022. The majority of people attend hospitals and clinics because they have access to doctors and equipment needed for cardiac surgery.
Figure 1 Cerebral Oximetry Monitoring Market, by End User, 2023 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Cerebral Oximetry Monitoring Market dominated this market in 2022 (45.80%). This can be attributable to the presence and offerings of significant players in the area. To monitor cerebral desaturation during cardiac surgery, oximeter devices including the INVOS System, ForeSight System, EQUANOX, and Root with O3 are commonly supplied in the United States by Medtronic, Edwards Lifesciences Corporation, Nonin, and Masimo. Further, the U.S. Cerebral Oximetry Monitoring market held the largest market share, and the Canada Cerebral Oximetry Monitoring market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 CEREBRAL OXIMETRY MONITORING MARKET SHARE BY REGION 2023 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Cerebral Oximetry Monitoring market accounted for the healthy market share in 2022. A desk-bound lifestyle devoid of exercise, a poor diet, anxiety, and stress that result in chronic illnesses like diabetes and obesity, as well as an increase in the prevalence of numerous cardiovascular diseases (CVD), are the main factors contributing to the growth of cerebral oximeters. Further, the German Cerebral Oximetry Monitoring market held the largest market share, and the U.K Cerebral Oximetry Monitoring market was the fastest growing market in the European region
The Asia Pacific Cerebral Oximetry Monitoring market is expected to register significant growth from 2024 to 2032. The region's ageing population, rising disease rates, and rising per capita disposable incomes are the main market-drivers in the area. Numerous studies have shown that older adults have a high risk of cardiovascular disease (CVD) because of their high comorbidity rates. According to a projection from the National Statistical Office, there would be 194 million senior people in the country by the end of 2021, up from 138 million in 2021. Moreover, China’s Cerebral Oximetry Monitoring market held the largest market share, and the Indian Cerebral Oximetry Monitoring market was the fastest growing market in the Asia-Pacific region.
Cerebral Oximetry Monitoring Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Cerebral Oximetry Monitoring market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Cerebral Oximetry Monitoring Industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Cerebral Oximetry Monitoring Industry to benefit clients and increase the market sector. In recent years, the Cerebral Oximetry Monitoring Industry has offered some of the most significant advantages to medicine. Major players in the Cerebral Oximetry Monitoring market, including Boston Scientific, Omron Healthcare, Welch Allyn, Honeywell Life Sciences, Natus Medical, Mindray Medical, Edwards Lifesciences, GE Healthcare, Masimo, Philips Healthcare, and Medtronic, are attempting to increase market demand by investing in research and development operations.
A medical technology firm called Medtronic Plc (Medtronic), originally known as Medtronic Inc., creates, develops, produces, and sells a variety of medical products. It provides products for the treatment of conditions such heart valve issues, heart failure, aortic, peripheral vascular, venous renal, and neurological problems, as well as spine and musculoskeletal issues, ear, nose, and throat conditions. Additionally, it offers biologic solutions for the dental and orthopaedic markets. In Asia Pacific, Europe, the Americas, the Middle East, and Africa, it provides its products to hospitals, third-party healthcare providers, clinics, institutions, including governmental health care programmes, distributors, and group purchasing organisations. The headquarters of Medtronic are in Dublin, Ireland. The INVOS 7100 cerebral/somatic oximetry device from Medtronic PLC received FDA 510(k) clearance for paediatric indications in December 2021. Paediatric clinicians who treat neonates, preterm infants, children, and other patients can make quick judgements on ventilation, hemodynamic management, and resuscitation with the use of the INVOS system.
A medical technology business called Masimo Corp. (Masimo) creates, produces, and sells non-invasive patient monitoring systems, medical equipment, and sensors to enhance patient care. The company's proprietary technologies include the rainbow SET platform and signal extraction technology (SET), which both assist in the detection of life-threatening occurrences. Patients monitors, pulse oximeters, central monitoring systems, specialised sensors, circuit boards, remote alerts, and monitoring solutions are some of its main products. Additionally, the business sells its goods directly to consumers as well as through a network of distributors and original equipment manufacturers that serve hospitals, long-term care facilities, veterinarian offices, emergency medical service providers, and home care providers. The corporation has operations in Australia, Asia, the Middle East, Europe, North and South America, and Africa. United States-based Masimo is based in Irvine, California. O3 Regional Oximetry was approved by the FDA for expanded usage in August 2020, according to Masimo. This includes monitoring somatic tissue oxygenation saturation in all patient populations as well as relative changes in haemoglobin, oxyhemoglobin, and deoxyhemoglobin in adult brains.
Key Companies in the Cerebral Oximetry Monitoring market include
Cerebral Oximetry Monitoring Industry Developments
August 2020 In order to monitor somatic tissue oxygenation saturation and compare variations in oxyhaemoglobin, haemoglobin, and deoxyhaemoglobin in adult brains, Masimo gained FDA authorization to enhance their "O3 Regional Oximetry" technology.
June 2022 Clinicians may now personalise care thanks to Medtronic's integration of two continuous monitoring technologies into the CARESCAPE platform from G.E. Healthcare. The ICU and surgical care will use the Microstream capnography and INVOS regional oximetry technology. The FDA has approved the integration, and the CE Mark has been obtained.
Cerebral Oximetry Monitoring Regional Outlook
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.11 Billion |
| Market Size 2024 | USD 0.12 Billion |
| Market Size 2032 | USD 0.19 Billion |
| Compound Annual Growth Rate (CAGR) | 7.10% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Age, Application, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Boston Scientific, Omron Healthcare, Welch Allyn, Honeywell Life Sciences, Natus Medical, Mindray Medical, Edwards Lifesciences, GE Healthcare, Masimo, Philips Healthcare, and Medtronic |
| Key Market Opportunities | Increasingly approved cerebral oximeters |
| Key Market Dynamics | The growing geriatric population and the increasing number of diseases such as cardiovascular and neurological disorders |
Cerebral Oximetry Monitoring Market Highlights:
Frequently Asked Questions (FAQ) :
The Cerebral Oximetry Monitoring market size was valued at USD 0.11 Billion in 2023.
The market is projected to grow at a CAGR of 7.10% during the forecast period, 2024-2032.
North America had the largest share in the market
The key players in the market are Boston Scientific, Omron Healthcare, Welch Allyn, Honeywell Life Sciences, Natus Medical, Mindray Medical, Edwards Lifesciences, GE Healthcare, Masimo, Philips Healthcare, and Medtronic
The Adults Age dominated the market in 2022.
The Cardiac Surgery Application had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
